Question special

While a goal is to prevent incidence of hip fracture, can you comment on the results of studies with romosozumab and hip fracture healing after fixation? I'm aware that the indication focus has shifted, but for the benefit of discussion and, perhaps, for readers less familiar with the data, were their subgroups or other analyses that showed who might benefit from romosozumab as an adjunctive treatment for faster fracture healing time? Is it something that may be considered in certain postmenopausal OP patients shortly after hip fx fixation who have fractured while already on another agent?